Oncology · Hematologic Malignancies
The facts most likely to be tested
The peripheral blood smear in Acute Myelogenous Leukemia (AML) classically reveals Auer rods, which are needle-like azurophilic cytoplasmic inclusions.
Bone marrow biopsy showing greater than 20% blasts is the diagnostic threshold for confirming a diagnosis of AML.
Acute Promyelocytic Leukemia (APL), a subtype of AML, is associated with the t(15;17) translocation and carries a high risk of disseminated intravascular coagulation (DIC).
All-trans retinoic acid (ATRA) is the specific, life-saving treatment for APL that induces differentiation of the malignant promyelocytes.
Patients with AML frequently present with pancytopenia, leading to clinical manifestations of fatigue, recurrent infections, and mucosal bleeding.
Myeloperoxidase (MPO) staining is the definitive histochemical marker used to differentiate myeloid blasts from lymphoid blasts.
Tumor lysis syndrome is a critical, life-threatening complication during induction chemotherapy, characterized by hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia.
Vignette unlocked
A 45-year-old male presents to the emergency department with a two-week history of progressive fatigue, night sweats, and easy bruising. Physical examination reveals gingival hyperplasia and multiple petechiae on the lower extremities. Laboratory studies demonstrate a hemoglobin of 7.2 g/dL, a platelet count of 22,000/µL, and a white blood cell count of 45,000/µL. A peripheral blood smear shows numerous myeloblasts containing Auer rods.
What is the most likely diagnosis?
Acute Myelogenous Leukemia (AML)
The presence of >20% blasts in the bone marrow (implied by the high peripheral blast count) combined with the pathognomonic finding of Auer rods confirms the diagnosis of AML.
Full handout
High yield triage
Etiology / Epidemiology
Primarily affects older adults (median age 65). Risk factors include prior chemotherapy (alkylating agents), radiation, and benzene exposure.
Clinical Manifestations
Presents with pancytopenia symptoms: fatigue, infection, and bleeding. Auer rods are the pathognomonic finding on peripheral smear.
Diagnosis
Bone marrow biopsy showing >20% myeloblasts is the diagnostic threshold.
Treatment
Induction therapy with cytarabine plus an anthracycline (e.g., daunorubicin). Tumor lysis syndrome is a major emergency.
Prognosis
Prognosis is highly variable based on cytogenetics; overall 5-year survival is approximately 25-30%.
Full handout
Epidemiology & Etiology
AML is the most common acute leukemia in adults, with incidence increasing significantly after age 60. Secondary AML often follows exposure to topoisomerase II inhibitors or alkylating agents used for prior malignancies. Genetic predispositions like Down syndrome (specifically M7 subtype) also increase risk.
Pertinent Anatomy
The disease originates in the bone marrow hematopoietic stem cells. Infiltration of the marrow space leads to the displacement of normal hematopoiesis, resulting in systemic cytopenias.
Pathophysiology
Malignant transformation of myeloid progenitor cells results in a maturation arrest. These immature myeloblasts proliferate uncontrollably, failing to differentiate into functional granulocytes, erythrocytes, or platelets. This leads to bone marrow failure and the clinical triad of anemia, neutropenia, and thrombocytopenia.
Clinical Manifestations
Patients present with constitutional symptoms including fever, night sweats, and weight loss. Physical exam may reveal gingival hyperplasia (common in M4/M5 subtypes), hepatosplenomegaly, and petechiae. Leukostasis is a medical emergency characterized by dyspnea and altered mental status due to hyperleukocytosis.
Diagnosis
The bone marrow biopsy is the gold standard for diagnosis, requiring >20% myeloblasts in the marrow or peripheral blood. Peripheral smear often reveals Auer rods, which are needle-like cytoplasmic inclusions. Flow cytometry is essential to confirm the myeloid lineage of the blasts.
Treatment
Induction therapy consists of the '7+3' regimen: cytarabine for 7 days and an anthracycline for 3 days. Tumor lysis syndrome requires aggressive IV hydration and allopurinol or rasburicase. Consolidation therapy follows to achieve long-term remission, often involving allogeneic stem cell transplant in high-risk patients.
Prognosis
Prognosis is dictated by cytogenetic markers; favorable markers include t(8;21), while unfavorable include complex karyotypes or FLT3 mutations. Disseminated intravascular coagulation (DIC) is a frequent, life-threatening complication, particularly in the APL (M3) subtype.
Differential Diagnosis
Acute Lymphoblastic Leukemia: usually pediatric, PAS-positive blasts
Chronic Myelogenous Leukemia: presence of Philadelphia chromosome, mature cells
Aplastic Anemia: hypocellular marrow without blast proliferation
Myelodysplastic Syndrome: <20% blasts, dysplastic morphology
Leukemoid Reaction: elevated WBC count due to infection, not malignancy